Andrew Norris
Senior Director, Research BCN Biosciences
Seminars
Wednesday 17th September 2025
Panel Discussion: Reducing Non-Responsiveness of RAS-Targeted Therapies by Delving into Mutation & Tissue Specific Impacts to Improve Drug Efficac
1:30 pm
• Uncovering factors within the tumor microenvironment which may result in non-responsiveness to
RAS-targeted therapies
• How do tissue specific interactions influence efficacy of RAS-targeting drugs?
• How do you successfully overcome or delay resistance to RAS-targeting therapies?
Thursday 18th September 2025
Improving Therapeutic Efficacy by Targeting the MAPK Pathway to Disrupt Tumor Growth & Reduce Oncogenesis
4:00 pm
- How to target specific MAPK substrates that are critical for tumor growth without disrupting broader cellular functions
- How does targeting upstream and downstream regulators of RAS signaling enhance drug efficacy?
- Addressing how alternative signaling pathways, particularly the PI3K/AKT pathway, contribute to resistance against MAPK-targeted therapies
